Skip to content

Other segment segments

Affordable Medicines
$28.01M-42.4%
Specialty
$9.06M+83.9%

Similar metrics at other companies

MSA
MSAInternational — R&D
$6.72M+6.6%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
JBT Marel Corporation logo
JBTMPrepared Food and Beverage Solutions — R&D
$7M-30.0%
Cummins logo
CMIAccelera — Research and Development Expense
$32M-25.6%
Indivior Pharmaceuticals, Inc.
 logo
INDVReportable Segment — R&D
$16M-27.3%
Axsome Therapeutics logo
AXSMAZD7325 — Research And Development Expense
$2.3M

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s avkare — R&D?
Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — R&D of $0 in Q1 2026.
What does avkare — R&D mean?
Represents expenditures incurred by the AvKARE segment to discover, develop, and improve pharmaceutical products or delivery systems. This metric indicates the segment's commitment to long-term innovation and its pipeline potential for future revenue streams.